Drug discovery companies identify, validate and develop new therapeutic candidates for the prevention and treatment of disease. The sector combines biology, chemistry, data science and clinical expertise to bring new medicines from concept to clinic.
This category includes companies working on:
Browse 422 UK drug discovery companies below.
Clinical-stage oncology biopharma developing the bispecific antibody ivonescimab
Summit Therapeutics is a clinical-stage oncology company with UK research operations originating from VASTox, a University of Oxford spin-out. The company's lead candidate,…
Immuno-oncology target discovery and antibody therapeutics developer
4C Biomed is a biotechnology company developing immuno-oncology therapies and target discovery platforms based on patient-derived tumour and immune cell systems. The company uses…
RNA immunotherapies targeting novel tumour-specific antigens
Epitopea is a biopharma company developing off-the-shelf RNA-based immunotherapies for hard-to-treat cancers. Using spatial immunopeptidomics, genomics, and systems…
Gene therapy biotech targeting neural circuit dysfunction
Sania Therapeutics is a biotechnology company developing genetic medicines for diseases caused by dysfunctional neural circuits. Its approach combines precision AAV delivery to…
Mechanobiology platform for target discovery and validation
Mechanome Bio is a Cambridge-based company developing a mechano-transcriptomics platform for biomarker and drug target discovery. The platform combines spatial multi-omics data…
Contract chemistry and manufacturing solutions for pharmaceutical and biotech research
Chemveda Life Sciences is a contract research and development organisation providing chemistry solutions to the pharmaceutical, biotechnology and agrochemical industries. The…
Ophthalmic therapeutics for presbyopia, cataracts, and geographic atrophy
Tenpoint Therapeutics is a clinical-stage biotechnology company developing therapeutics for age-related ocular diseases. Its pipeline comprises three programmes: BRIMOCHOL PF, a…
Genome-editing platform mapping cancer drug resistance and druggable vulnerabilities
BASE Rx is a Wellcome Sanger Institute spin-out applying genome-editing and DNA sequencing technologies to cancer drug discovery. The company maps single-base genetic variants to…
AI drug discovery platform developing novel biologics for cancer and AMR
AMPLY Discovery is a biotechnology company developing an AI-driven drug discovery platform that combines machine learning, next-generation sequencing, and synthetic biology to…
Small activating RNA therapeutics for gene upregulation and disease
MiNA Therapeutics is a clinical-stage biotechnology company pioneering small activating RNA medicines, a class of oligonucleotide therapeutics that restore or boost expression of…
Synthetic glycan-targeted small molecules for next-generation immunotherapy
Anomer Bio is a biotechnology company developing synthetic monosaccharides and small molecule drugs that target glycans, the sugars coating cell surfaces that influence immune…
Cocrystal drug repurposing for oncology supportive care and fibrosis
Nuformix is a pharmaceutical development company using proprietary cocrystal technology to repurpose existing drugs for unmet medical needs in fibrosis and oncology. By…